Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.

The conversation humorously discusses the effects of DHT on hair loss, with references to treatments like finasteride and RU58841. Users share exaggerated stories about DHT's impact, highlighting its negative reputation.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

The conversation is about using alfatradiol for hair loss treatment. One user combined it with oral finasteride but noticed no significant difference.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The user experienced significant hair density improvement and darker hair color after four months of taking 1mg finasteride daily, but also noticed temple recession. They started using oral castor oil and microneedling, hoping to prevent further temple recession.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.

User shares progress after 4 months of using finasteride and dermarolling, with occasional use of coconut and rosemary oil. They aim to stop hair loss and hope for increased top density.

Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.

A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Ultrasound imaging can non-invasively detect active and inactive hair follicles, inflammation, and fibrosis, potentially reducing unnecessary biopsies. It may help assess hair growth potential and diagnose scalp issues, but some users believe in trying treatments regardless of ultrasound results.

A user expressed satisfaction with a hair and beard transplant at HairofIstanbul using 3200 grafts and PRP, achieving natural-looking results without finasteride or minoxidil. The transformation was praised, though some noted the beard line appeared artificial.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The user experienced hair improvement using 1mg finasteride daily for six months, managing seborrheic dermatitis with rosemary and eucalyptus oil. They are considering switching to dutasteride for potentially better results.

The user experienced better results with Ell-Cranell (0.025% alfatradiol) compared to Farmacia Tristaina’s 0.2% alfatradiol solution, which seemed less effective in reducing hair loss. They questioned the efficacy of the compounded solution due to continued shedding and lack of side effects.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.